MEDCOMM : Impact Factor & More
eISSN: 2688-2663pISSN: 2688-2663
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on MEDCOMM
MEDCOMM Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Article-by-article |
| Article Processing Charges | USD 2900 |
| Publication Time | 10 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Sichuan International Medical Exchange & Promotion Association (SCIMEA) |
| Frequency | Article-by-article |
| Publication Start Year | 2020 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in MEDCOMM ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in MEDCOMM
Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies.
- 1 May 2026
- MedComm
CAR-T Cells: Current Status, Challenges, and Future Prospects.
- 1 May 2026
- MedComm
XIAP Deficiency Impairs Colonic Tuft Cell Development and Predisposes to Crohn's Disease.
- 1 May 2026
- MedComm
Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies.
- 1 May 2026
- MedComm
Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions.
- 1 May 2026
- MedComm
MRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.
- 1 May 2026
- MedComm
Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies.
- 1 May 2026
- MedComm
CAR-T Cells: Current Status, Challenges, and Future Prospects.
- 1 May 2026
- MedComm
XIAP Deficiency Impairs Colonic Tuft Cell Development and Predisposes to Crohn's Disease.
- 1 May 2026
- MedComm
Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies.
- 1 May 2026
- MedComm
Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions.
- 1 May 2026
- MedComm
MRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.
- 1 May 2026
- MedComm
FAQs on MEDCOMM
How long has MEDCOMM been actively publishing? 
What is the publishing frequency of MEDCOMM?
How many articles did MEDCOMM publish last year?
What is the eISSN & pISSN for MEDCOMM?
Who is the publisher of MEDCOMM?
